Evidence map›Paper›PMID 34244513›Full record

Observational studyNature communications2021

Multiplexed functional genomic analysis of 5' untranslated region mutations across the spectrum of prostate cancer.

Yiting Lim, Sonali Arora, Samantha L Schuster, Lukas Corey, Matthew Fitzgibbon, Cynthia L Wladyka, Xiaoying Wu, Ilsa M Coleman, Jeffrey J Delrow, Eva Corey and 4 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 74 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Marine life science & technology · 2024
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Yiting LimDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0003-3067-6362
Sonali AroraDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0002-6661-3024
Samantha L SchusterDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0003-4051-5802
Lukas CoreyDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Matthew FitzgibbonGenomics and Bioinformatics Shared Resource, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Cynthia L WladykaDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Xiaoying WuDivision of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Ilsa M ColemanDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jeffrey J DelrowGenomics and Bioinformatics Shared Resource, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0003-1020-3154
Eva CoreyDepartment of Urology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-9244-3807
Lawrence D TrueDepartment of Urology, University of Washington, Seattle, WA, USA.
Peter S NelsonDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0002-5451-5726
Gavin HaDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0001-7578-7272
Andrew C HsiehDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ahsieh@fredhutch.org.ORCID 0000-0002-0897-1050
Fred Hutch Cancer Center · USUniversity of Washington · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZA

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
TRAINING IN MOLECULAR AND CELLULAR BIOLOGYT32GM007270 · NIGMS · UNIVERSITY OF WASHINGTON · PI RAIBLE, DAVID W · 1985 to 2020
$21.0M
The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2017 to 2021
$6.8M
The MYC Transcription Factor Network and the Path to CancerR35CA231989 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI EISENMAN, ROBERT NEIL · 2018 to 2024
$6.3M
Hormone signaling and translation control in advanced prostate cancerR37CA230617 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HSIEH, ANDREW CALEB · 2019 to 2025
$3.1M
Selective mRNA translation in developmental disordersR01GM135362 · NIGMS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BERONJA, SLOBODAN, HSIEH, ANDREW CALEB · 2020 to 2023
$2.1M
Defining and Targeting Lineage Transition Programs Operative in AR Pathway Independent Prostate CancerR01CA234715 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NELSON, PETER S · 2020 to 2024
$2.0M
High-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0M
Epitranscriptomic control of erythropoiesisR01DK119270 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PADDISON, PATRICK · 2019 to 2022
$1.8M
Elucidating the role of somatic 3’UTR mutations in prostate cancer pathogenesisF31CA260920 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SCHUSTER, SAMANTHA LEE · 2021 to 2023
$98k
NCI NIH HHS F31 CA260920NCI NIH HHS P30 CA015704NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA234715NCI NIH HHS R35 CA231989NCI NIH HHS R37 CA230617NCI NIH HHS U54 CA224079NIDDK NIH HHS R01 DK119270NIGMS NIH HHS R01 GM135362NIGMS NIH HHS T32 GM007270NIH HHS S10 OD028685
6 · The paper itself

Abstract

The functional consequences of genetic variants within 5' untranslated regions (UTRs) on a genome-wide scale are poorly understood in disease. Here we develop a high-throughput multi-layer functional genomics method called PLUMAGE (Pooled full-length UTR Multiplex Assay on Gene Expression) to quantify the molecular consequences of somatic 5' UTR mutations in human prostate cancer. We show that 5' UTR mutations can control transcript levels and mRNA translation rates through the creation of DNA binding elements or RNA-based cis-regulatory motifs. We discover that point mutations can simultaneously impact transcript and translation levels of the same gene. We provide evidence that functional 5' UTR mutations in the MAP kinase signaling pathway can upregulate pathway-specific gene expression and are associated with clinical outcomes. Our study reveals the diverse mechanisms by which the mutational landscape of 5' UTRs can co-opt gene expression and demonstrates that single nucleotide alterations within 5' UTRs are functional in cancer.

Indexed as

Gene Expression Regulation, Neoplastic5' Untranslated RegionsCell Line, TumorDNA Mutational AnalysisGenomicsHEK293 CellsHigh-Throughput Screening AssaysHumansMalePoint MutationProstateProstatic NeoplasmsProtein BiosynthesisRNA-Seq5' Untranslated Regions

Identifiers

PMID34244513
PMCPMC8270899
OpenAlexW3178196354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.